MX2012012032A - Inhibidores de la actividad de la proteina tirosina quinasa. - Google Patents

Inhibidores de la actividad de la proteina tirosina quinasa.

Info

Publication number
MX2012012032A
MX2012012032A MX2012012032A MX2012012032A MX2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A MX 2012012032 A MX2012012032 A MX 2012012032A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
kinase activity
protein tyrosine
inhibitors
compounds
Prior art date
Application number
MX2012012032A
Other languages
English (en)
Inventor
Norifumi Sato
Lijie Zhan
Stephen William Claridge
Franck Raeppel
Arkadii Vaisburg
Michael Mannion
Frederic Gaudette
Masashi Kishida
Yohei Yuki
Stephene Raeppel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MX2012012032A publication Critical patent/MX2012012032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa; En particular, la invención se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa de los receptores de los factores de crecimiento, lo que da como resultado la inhibición de la señalización del receptor, por ejemplo, la inhibición de la señalización del receptor del VEGF (factor de crecimiento endotelial vascular); La invención también proporciona compuestos, composiciones y métodos para el tratamiento de enfermedades y condiciones de proliferación de células y enfermedades, desordenes o condiciones oftálmicas.
MX2012012032A 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa. MX2012012032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
MX2012012032A true MX2012012032A (es) 2012-12-17

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012032A MX2012012032A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa.
MX2012012031A MX2012012031A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012012031A MX2012012031A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.

Country Status (18)

Country Link
US (3) US8455484B2 (es)
EP (2) EP2563795A4 (es)
JP (2) JP2013523846A (es)
KR (2) KR20130058006A (es)
CN (2) CN103025740B (es)
AR (2) AR080871A1 (es)
AU (2) AU2011241420B2 (es)
CA (2) CA2796008A1 (es)
CO (2) CO6630193A2 (es)
EA (2) EA201291052A1 (es)
MX (2) MX2012012032A (es)
MY (1) MY157319A (es)
NZ (2) NZ602954A (es)
SG (2) SG184882A1 (es)
TW (2) TW201204735A (es)
UA (1) UA108878C2 (es)
WO (2) WO2011127565A1 (es)
ZA (2) ZA201207482B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
AU2009221583B2 (en) * 2008-03-05 2013-06-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN103025740B (zh) * 2010-04-16 2015-07-01 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
AU2005266803B2 (en) * 2004-07-30 2011-10-27 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610382A2 (pt) * 2005-05-20 2010-06-15 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
EP2183255A4 (en) * 2007-08-29 2011-06-15 Methylgene Inc METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
AU2009221583B2 (en) 2008-03-05 2013-06-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CN103025740B (zh) * 2010-04-16 2015-07-01 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
AU2011241422B2 (en) 2015-05-07
US20110257175A1 (en) 2011-10-20
NZ602948A (en) 2014-09-26
CO6640224A2 (es) 2013-03-22
CN103025740B (zh) 2015-07-01
CO6630193A2 (es) 2013-03-01
AU2011241420B2 (en) 2015-04-16
US20110257100A1 (en) 2011-10-20
CA2796008A1 (en) 2011-10-20
JP2013523846A (ja) 2013-06-17
AR080875A1 (es) 2012-05-16
AR080871A1 (es) 2012-05-16
US20140315801A1 (en) 2014-10-23
ZA201207482B (en) 2013-09-25
CA2796054A1 (en) 2011-10-20
WO2011127565A1 (en) 2011-10-20
JP2013525286A (ja) 2013-06-20
EP2563794A4 (en) 2013-12-04
CN102947315A (zh) 2013-02-27
EP2563795A4 (en) 2013-10-23
ZA201207557B (en) 2013-06-26
NZ602954A (en) 2014-11-28
TW201204734A (en) 2012-02-01
EP2563795A1 (en) 2013-03-06
KR20130100234A (ko) 2013-09-10
UA108878C2 (ru) 2015-06-25
MX2012012031A (es) 2012-12-17
CN103025740A (zh) 2013-04-03
EA201291055A1 (ru) 2013-09-30
WO2011127567A1 (en) 2011-10-20
KR20130058006A (ko) 2013-06-03
EA201291052A1 (ru) 2013-04-30
SG184882A1 (en) 2012-11-29
US8906852B2 (en) 2014-12-09
SG184883A1 (en) 2012-11-29
AU2011241422A1 (en) 2012-11-01
MY157319A (en) 2016-05-31
TW201204735A (en) 2012-02-01
EP2563794A1 (en) 2013-03-06
US8455484B2 (en) 2013-06-04

Similar Documents

Publication Publication Date Title
UA100262C2 (uk) Інгібітори активності протеїнтирозинкінази
MX2012012032A (es) Inhibidores de la actividad de la proteina tirosina quinasa.
WO2008035209A3 (en) Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
WO2007149427A3 (en) Tyrosine kinase inhibitors
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
NZ755605A (en) Compositions for modulating tau expression
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
MX352844B (es) Compuestos de quinolina sustituidos y metodos de uso.
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EA201300080A1 (ru) Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
WO2014110198A3 (en) Therapeutic indications of kinase inhibitors
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MY165216A (en) Quinoline derivatives as pde10a enzyme inhibitors
MY159995A (en) Pyrimidinyl indole compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal